RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:2089

Glycogen storage disease due to hepatic glycogen synthase deficiency

low confidenceDisorder

Also known as: GSD due to hepatic glycogen synthase deficiency · GSD type 0a · Glycogen storage disease due to liver glycogen synthase deficiency · Glycogen storage disease type 0a · Glycogenosis type 0a

Publications

1,303

Trials

1

Interventional, condition-specific

Researchers

484

Distinct authors in sample

Gene link

GYS2

Definitive

Readiness

4/6

Stages with a signal

Clinical definition (Orphanet)

A rare genetically inherited anomaly of glycogen metabolism, considered a form of glycogen storage disease (GSD, or glycogenosis), characterized by post-meal hyperglycemia and fasting . This is not a glycogenosis, strictly speaking, as there is no storage of glycogen, the deficiency preventing hepatic glycogen synthesis.

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (7)

glycogen storage disease due to glycogen synthase deficiency of liver · glycogen storage disease due to hepatic glycogen synthase deficiency · glycogen storage disease due to liver glycogen synthase deficiency · glycogen storage disease type 0a · glycogen synthase deficiency · glycogenosis type 0a · liver glycogen storage disease due to glycogen synthase deficiency

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

4/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedPresent

    Definitive — GYS2

  2. LiteraturePresent

    1,303 matched papers (979 in last 10 years) Source

  3. Phenotype characterisedPresent

    20 HPO annotations (e.g. Elevated circulating hepatic transaminase concentration; Seizure; Increased circulating lactate concentration) Source

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationNot found

    No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source

  6. Interventional trialPresent

    1 matched on ClinicalTrials.gov

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (GYS2).

GenCC classification: Definitive.

Phenotypes (Monarch / HPO)

20

Associated phenotypes · MONDO:0009414

  • Elevated circulating hepatic transaminase concentration
  • Seizure
  • Increased circulating lactate concentration
  • Neonatal hypoglycemia
  • Postprandial hyperglycemia

Showing 5 of 20 — open Monarch for the full list.

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.

Open Targets candidates

No drugs or clinical candidates returned for this Mondo ID on Open Targets.

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

1,303

1,303 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

1,303 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

979 in the last 10 years · low confidence

Phrase hits: 79 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

484

Distinct author names in 79 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Weinstein DA7 papers · 2025

    Glycogen Storage Disease Program, University of Florida College of Medicine, Gainesville, FL.

    Papers in Europe PMC
  2. 02
    Derks TGJ5 papers · 2025

    Section of Metabolic Diseases, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, PO box 30 001, 9700, RB, Groningen, the Netherlands.

    Papers in Europe PMC
  3. 03
    Shah P4 papers · 2025

    Genetics and Genomic Medicine Programme, UCL Great Ormond Street Institute of Child Health, Great Ormond Street, London, WC1N 3JH, UK. pratik.shah6@nhs.net.

    Papers in Europe PMC
  4. 04
    Wolfsdorf JI4 papers · 2025

    Division of Endocrinology, Boston Children's Hospital, Boston, MA.

    Papers in Europe PMC
  5. 05
    Bosshard NU3 papers · 2001
    Papers in Europe PMC
  6. 06
    Christesen HT3 papers · 2021

    Hans Christian Andersen Children's Hospital, Odense University Hospital, Odense, Denmark.

    Papers in Europe PMC
  7. 07
    Drachmann D3 papers · 2025

    Ketotic Hypoglycemia International (KHI), Skanderborg, Denmark.

    Papers in Europe PMC
  8. 08
    Rokicki D3 papers · 2024

    Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, The Children's Memorial Health Institute, Warsaw, Poland.

    Papers in Europe PMC
  9. 09
    Byrne BJ2 papers · 2024

    Department of Pediatrics, Powell Gene Therapy Center, College of Medicine, University of Florida, Gainesville, Florida, USA.

    Papers in Europe PMC
  10. 10
    Carrigg A2 papers · 2021

    Ketotic Hypoglycemia International (KHI), Skanderborg, Denmark.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

1

interventional trials for this specific condition

1 interventional trial matched this specific condition name; none in our sample are currently recruiting.

Data as of 11 September 2026 · last trial check 28 July 2026

1 interventional trial — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 80.1th percentile).

low confidence · 80.1th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

1 interventional trials matched after quoted-phrase search and title/condition post-filter.

No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.

Observational and natural-history studies

1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-29

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Glycogen storage disease due to hepatic glycogen synthase deficiency — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

("Glycogen storage disease due to hepatic glycogen synthase deficiency" OR "GSD due to hepatic glycogen synthase deficiency" OR "GSD type 0a" OR "Glycogen storage disease due to liver glycogen synthase deficiency" OR "Glycogen storage disease type 0a" OR "Glycogenosis type 0a" OR "glycogen storage disease due to glycogen synthase deficiency of liver" OR "glycogen storage disease due to glycogen synthase deficiency of the liver" OR "glycogen synthase deficiency" OR "liver glycogen storage disease due to glycogen synthase deficiency") OR ("GYS2" OR "GYS2 syndrome" OR "GYS2-related")

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Glycogen storage disease due to hepatic glycogen synthase deficiency" OR "GSD due to hepatic glycogen synthase deficiency" OR "GSD type 0a" OR "Glycogen storage disease due to liver glycogen synthase deficiency" OR "Glycogen storage disease type 0a" OR "Glycogenosis type 0a" OR "glycogen storage disease due to glycogen synthase deficiency of liver" OR "glycogen storage disease due to glycogen synthase deficiency of the liver" OR "glycogen synthase deficiency" OR "liver glycogen storage disease due to glycogen synthase deficiency"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 1 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (1303) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity

Ingested 2026-07-26T19:04:53.468Z